Digital & Decentralized Finance, Blockchain Daily News


              



Smart Pharma Token (SMPT) Debuts Its Initial Listing On IDAX: Global Blockchain Cryptocurrencies Trading Exchange Platform


Smart Pharma Group, a subsidiary group of Aptorum Group Limited (Nasdaq: APM), is excited to share that our Smart Pharma Token (“SMPT token”), traded publicly for the first time at 2:00 pm, 10 July 2019 (UTC+8:00), on IDAX (https://www.idax.pro/).



Trading is initially open for trading across SMPT/BTC (Bitcoin) and SMPT/ETH (Ethereum) trading pairs only; and SMPT debuted at the equivalent price of about US$0.025 per token. As at 12:00 am, 11 July 2019 (UTC+8:00), the token is trading in Dollar terms at about US$0.0253 per token

Based on valuation methodologies and assumptions described in the Smart Pharma Token (SMPT) Token Economy Appendix (https://www.smtph.io/doc/token-paper.pdf?v=2.2), the debut price of US$0.025 and referenced trading price of US$0.0253 per token, currently values the underlying repurposed and new drug discovery platform, Smart-ACT™ between US$169 million and US$171 million. Since the tokens are not a liquid market, this valuation is merely an estimate based upon the prices noted herein and we have not made any independent verification of such valuation; there is no guarantee that such valuation will be maintained.

More details on SMPT and Smart-ACT™ are provided below.

About the SMPT token:
The SMPT token is an ERC-1404 security compliant token with ERC-20 and ERC233 compliance on the Ethereum blockchain. SMPT tokenizes rights to a portion of the royalty income derived from the eventual commercialization of intellectual property rights of drug candidates to be discovered under our Smart-ACT™ platform.

About the Smart-ACT™ platform:
The Smart-ACT™ platform is a repurposed and new drug discovery platform launched by the Smart Pharma Group which intends to revolutionize drug discovery, repurposing and repositioning. In the forthcoming developments, Smart Pharma Group would include the incorporation of blockchain technology into the drug development and discovery processes, initially through the adoption of the SMPT token as the first step. We believe that blockchain technology will significantly increase data transparency and bring distributed power from participants worldwide to co-develop and evolve our next Smart-ACT™ platform technology.
Smart Pharma Group recognizes that blockchain-based technology will continue to play an important role in pharmaceutical development and also has the capability to foster community-based ecosystems of passionate and like-minded people in revolutionizing the drug discovery industry who would like to be an integral part of the process around projects.

www.smtph.com

About Smart Pharma Group
Smart Pharma Group includes Smart Pharmaceutical Limited Partnership, a limited partnership registered in Seychelles, and its general partner, SMTPH Limited, an international business company incorporated under the laws of Seychelles. SMTPH Limited and its subsidiaries are indirectly wholly owned by Aptorum Group Limited.

Disclaimer
The SMPT tokens are currently not offered for sale to citizens, nationals, residents (tax or otherwise), green card holders and/or companies domiciled in the following: (a) the United States of America; (b) Singapore; (c) Hong Kong (except for Professional Investors); (d) the People’s Republic of China; (e) Samoa, (f) Seychelles, (g) sanctioned countries under the OFAC and (h) any other jurisdiction which prohibits the possession, dissemination or communication of the Whitepaper.
Statements, estimates and financial information contained hereunder, on our website http://www.SMTPH.com, made in any announcements or in any place accessible by the public and oral statements that may be made by the Smart Pharma Group may constitute forward-looking statements. Smart Pharma Group disclaims any responsibility to update any of these forward-looking statements or publicly announce any revisions to these forward-looking statements to reflect future developments, events or circumstances, even if new information becomes available or other events occur in the future.
This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which the offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

FINYEAR & CHAINEUM

Lisez gratuitement le quotidien Finyear & sa newsletter quotidienne.
Recevez chaque matin par mail la newsletter Finyear, une sélection quotidienne des meilleures infos et expertises en finance digitale, corporate finance & crypto finance.

Read for free The daily newspaper Finyear & its daily newsletter.
Receive the Finyear's newsletter every morning by email, a daily snapshot of the best news and expertise in digital finance, corporate finance & crypto finance.

------------------------

Chaineum :
Fondée en 2015, Chaineum est un cabinet de conseil en opérations de haut de bilan offrant une expertise de premier plan en matière d’ICO et STO, avec une vision stratégique orientée tant vers le métier de ses clients que sur la technologie blockchain. A ce titre, Chaineum a participé à la mise en œuvre de bonnes pratiques dans le secteur (ICO Charter, Security Token Network).
La division services blockchain de Chaineum, développe la technologie Chaineum Segment, une blockchain privée orientée objets.

About Chaineum:
Founded in 2015, Chaineum is a leading corporate finance advisory firm with a strong expertise in ICO and STO, and a strategic focus on both its clients' business and blockchain technology. As such, Chaineum paved the way in the implementation of certain best practices in this sector (ICO Charter, Security Token Network).
Chaineum's blockchain services division, is developing Chaineum Segment technology, an object-oriented private blockchain.

-------------------------

No Offer, Solicitation, Investment Advice, or Recommendations

This website is for informational purposes only and does not constitute an offer to sell, a solicitation to buy, or a recommendation for any security, nor does it constitute an offer to provide investment advisory or other services by FINYEAR.
No reference to any specific security constitutes a recommendation to buy, sell or hold that security or any other security.
Nothing on this website shall be considered a solicitation or offer to buy or sell any security, future, option or other financial instrument or to offer or provide any investment advice or service to any person in any jurisdiction.
Nothing contained on the website constitutes investment advice or offers any opinion with respect to the suitability of any security, and the views expressed on this website should not be taken as advice to buy, sell or hold any security. In preparing the information contained in this website, we have not taken into account the investment needs, objectives and financial circumstances of any particular investor.
This information has no regard to the specific investment objectives, financial situation and particular needs of any specific recipient of this information and investments discussed may not be suitable for all investors.
Any views expressed on this website by us were prepared based upon the information available to us at the time such views were written. Changed or additional information could cause such views to change.
All information is subject to possible correction. Information may quickly become unreliable for various reasons, including changes in market conditions or economic circumstances.

Vendredi 12 Juillet 2019
Notez


Nouveau commentaire :
Twitter

Your email address will not be published. Required fields are marked *
Votre adresse de messagerie ne sera pas publiée. Les champs obligatoires sont indiqués avec *

Finyear: latest news, derniers articles

Free Daily Newsletter / Newsletter quotidienne gratuite


Cryptocurrencies



Finyear - Daily News